



## Clinical trial results:

### A Randomized, Double-blind, Double-dummy, Multicenter, Adaptive Design, Dose Escalation (Part 1) and Dose-Response (Part 2) Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery

#### Summary

EudraCT number	2016-004550-15
Trial protocol	BE ES PL LV LT BG GR PT IT RO
Global end of trial date	05 November 2018

#### Results information

Result version number	v1 (current)
This version publication date	27 November 2019
First version publication date	27 November 2019

#### Trial information

##### Trial identification

Sponsor protocol code	64179375THR2001
-----------------------	-----------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03251482
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Janssen Research & Development, LLC
Sponsor organisation address	920 Route 202, Raritan, United States, NJ 08869
Public contact	Clinical Registry group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com
Scientific contact	Clinical Registry group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	05 November 2018
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	05 November 2018
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

The primary objective for Part 1 was to assess in men and women undergoing primary unilateral total knee replacement (TKR) surgery the safety and tolerability of JNJ-64179375 for each dose level for dose escalation within Part 1 and any bleeding events (the composite of major, clinically relevant nonmajor [CRNM], and minimal bleeding events) for the selection of doses for Part 2 and for Part 2 was to assess in men and women undergoing primary unilateral total knee replacement (TKR) surgery the efficacy dose-response of JNJ-64179375 for the prevention of total venous thromboembolism (VTE) (proximal and/or distal deep vein thrombosis (DVT) [asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic], nonfatal pulmonary embolism [PE], or any death).

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements. Safety evaluations included the monitoring of all non-serious and serious adverse events (AEs), (including AEs of special interest: suspected symptomatic efficacy (thrombotic) events, bleeding events, infusion reactions, hypersensitivity reactions, and wound or joint complications), clinical laboratory tests (ie, hematology, clinical chemistry, urinalysis), vital signs measurements (blood pressure, pulse/heart rate, temperature), and physical examinations.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	20 November 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 27
Country: Number of subjects enrolled	Belgium: 16
Country: Number of subjects enrolled	Bulgaria: 2
Country: Number of subjects enrolled	Canada: 3
Country: Number of subjects enrolled	Spain: 18
Country: Number of subjects enrolled	Italy: 8
Country: Number of subjects enrolled	Japan: 12
Country: Number of subjects enrolled	Lithuania: 12
Country: Number of subjects enrolled	Latvia: 12
Country: Number of subjects enrolled	Malaysia: 4
Country: Number of subjects enrolled	Poland: 60
Country: Number of subjects enrolled	Russian Federation: 14
Country: Number of subjects enrolled	Turkey: 23

Country: Number of subjects enrolled	Ukraine: 38
Country: Number of subjects enrolled	United States: 56
Worldwide total number of subjects	305
EEA total number of subjects	128

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	128
From 65 to 84 years	173
85 years and over	4

## Subject disposition

### Recruitment

Recruitment details:

A total of 360 subjects were screened. Of those, 308 subjects were randomized: 245 subjects to JNJ-64179375 intravenous (IV) doses and 63 subjects to the apixaban dose. The safety analysis set included 305 of the 308 subjects (99.0%) who were treated with study drug.

### Pre-assignment

Screening details:

The study was planned to be conducted in 2 parts: Part 1 (Dose- Escalation) and Part 2 (Dose-Response). After completion of Part 1, the sponsor made the decision to not move forward with Part 2 as there was sufficient data to make a determination of efficacy in Part 1. Part 2 was not conducted, hence endpoints for Part 2 are not reported.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	JNJ-64179375 0.3 mg/kg and Apixaban Placebo

Arm description:

Subjects received a single intravenous (IV) infusion of JNJ-64179375 0.3 milligrams per kilogram (mg/kg) on Day 1 and matching apixaban placebo tablets orally twice daily (BID) for 10 to 14 days.

Arm type	Experimental
Investigational medicinal product name	JNJ-64179375 0.3 mg/kg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received a single IV infusion of JNJ-64179375 0.3 mg/kg on Day 1.

Investigational medicinal product name	Apixaban Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received matching apixaban placebo tablets BID for 10 to 14 days.

<b>Arm title</b>	JNJ-64179375 0.6 mg/kg and Apixaban Placebo
------------------	---

Arm description:

Subjects received a single IV infusion of JNJ-64179375 0.6 mg/kg on Day 1 and matching apixaban placebo tablets orally BID for 10 to 14 days.

Arm type	Experimental
Investigational medicinal product name	JNJ-64179375 0.6 mg/kg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:	
Subjects received a single IV infusion of JNJ-64179375 0.6 mg/kg on Day 1.	
Investigational medicinal product name	Apixaban Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Subjects received matching apixaban placebo tablets BID for 10 to 14 days.	
<b>Arm title</b>	JNJ-64179375 1.2 mg/kg and Apixaban Placebo
Arm description:	
Subjects received a single IV infusion of JNJ-64179375 1.2 mg/kg on Day 1 and matching apixaban placebo tablets orally BID for 10 to 14 days.	
Arm type	Experimental
Investigational medicinal product name	JNJ-6417937 1.2 mg/kg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Subjects received a single IV infusion of JNJ-64179375 1.2 mg/kg on Day 1.	
Investigational medicinal product name	Apixaban Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Subjects received matching apixaban placebo tablets BID for 10 to 14 days.	
<b>Arm title</b>	JNJ-64179375 1.8 mg/kg and Apixaban Placebo
Arm description:	
Subjects received a single IV infusion of JNJ-64179375 1.8 mg/kg on Day 1 and matching apixaban placebo tablets orally BID for 10 to 14 days.	
Arm type	Experimental
Investigational medicinal product name	Apixaban Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
Subjects received matching apixaban placebo tablets BID for 10 to 14 days.	
Investigational medicinal product name	JNJ-64179375 1.8 mg/kg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use
Dosage and administration details:	
Subjects received a single IV infusion of JNJ-64179375 1.8 mg/kg on Day 1.	
<b>Arm title</b>	Apixaban 2.5 mg and JNJ-64179375 Placebo IV
Arm description:	
Subjects received a single IV infusion of matching JNJ-64179375 placebo on Day 1 and apixaban 2.5 mg tablet orally BID for 10 to 14 days.	
Arm type	Active comparator

Investigational medicinal product name	JNJ-64179375 Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received a single IV infusion of matching JNJ-64179375 placebo on Day 1.

Investigational medicinal product name	Apixaban 2.5 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received an oral dose of apixaban 2.5 mg tablets BID for 10 to 14 days.

<b>Number of subjects in period 1</b>	JNJ-64179375 0.3 mg/kg and Apixaban Placebo	JNJ-64179375 0.6 mg/kg and Apixaban Placebo	JNJ-64179375 1.2 mg/kg and Apixaban Placebo
Started	38	40	42
Completed	38	40	42

<b>Number of subjects in period 1</b>	JNJ-64179375 1.8 mg/kg and Apixaban Placebo	Apixaban 2.5 mg and JNJ-64179375 Placebo IV
Started	122	63
Completed	122	63

## Baseline characteristics

### Reporting groups

Reporting group title	JNJ-64179375 0.3 mg/kg and Apixaban Placebo
Reporting group description: Subjects received a single intravenous (IV) infusion of JNJ-64179375 0.3 milligrams per kilogram (mg/kg) on Day 1 and matching apixaban placebo tablets orally twice daily (BID) for 10 to 14 days.	
Reporting group title	JNJ-64179375 0.6 mg/kg and Apixaban Placebo
Reporting group description: Subjects received a single IV infusion of JNJ-64179375 0.6 mg/kg on Day 1 and matching apixaban placebo tablets orally BID for 10 to 14 days.	
Reporting group title	JNJ-64179375 1.2 mg/kg and Apixaban Placebo
Reporting group description: Subjects received a single IV infusion of JNJ-64179375 1.2 mg/kg on Day 1 and matching apixaban placebo tablets orally BID for 10 to 14 days.	
Reporting group title	JNJ-64179375 1.8 mg/kg and Apixaban Placebo
Reporting group description: Subjects received a single IV infusion of JNJ-64179375 1.8 mg/kg on Day 1 and matching apixaban placebo tablets orally BID for 10 to 14 days.	
Reporting group title	Apixaban 2.5 mg and JNJ-64179375 Placebo IV
Reporting group description: Subjects received a single IV infusion of matching JNJ-64179375 placebo on Day 1 and apixaban 2.5 mg tablet orally BID for 10 to 14 days.	

Reporting group values	JNJ-64179375 0.3 mg/kg and Apixaban Placebo	JNJ-64179375 0.6 mg/kg and Apixaban Placebo	JNJ-64179375 1.2 mg/kg and Apixaban Placebo
Number of subjects	38	40	42
Title for AgeCategorical Units: subjects			
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	16	20	13
From 65 to 84 years	22	19	29
85 years and over	0	1	0
Title for AgeContinuous Units: years			
arithmetic mean	66.2	65.8	66.9
standard deviation	± 7.53	± 8.14	± 6.41
Title for Gender Units: subjects			
Female	21	25	35
Male	17	15	7

Reporting group values	JNJ-64179375 1.8 mg/kg and Apixaban Placebo	Apixaban 2.5 mg and JNJ-64179375 Placebo IV	Total
Number of subjects	122	63	305
Title for AgeCategorical Units: subjects			
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0

Adults (18-64 years)	49	30	128
From 65 to 84 years	70	33	173
85 years and over	3	0	4
Title for AgeContinuous Units: years			
arithmetic mean	67.2	65.1	
standard deviation	± 8.84	± 7.01	-
Title for Gender Units: subjects			
Female	99	42	222
Male	23	21	83



## End points

### End points reporting groups

Reporting group title	JNJ-64179375 0.3 mg/kg and Apixaban Placebo
Reporting group description: Subjects received a single intravenous (IV) infusion of JNJ-64179375 0.3 milligrams per kilogram (mg/kg) on Day 1 and matching apixaban placebo tablets orally twice daily (BID) for 10 to 14 days.	
Reporting group title	JNJ-64179375 0.6 mg/kg and Apixaban Placebo
Reporting group description: Subjects received a single IV infusion of JNJ-64179375 0.6 mg/kg on Day 1 and matching apixaban placebo tablets orally BID for 10 to 14 days.	
Reporting group title	JNJ-64179375 1.2 mg/kg and Apixaban Placebo
Reporting group description: Subjects received a single IV infusion of JNJ-64179375 1.2 mg/kg on Day 1 and matching apixaban placebo tablets orally BID for 10 to 14 days.	
Reporting group title	JNJ-64179375 1.8 mg/kg and Apixaban Placebo
Reporting group description: Subjects received a single IV infusion of JNJ-64179375 1.8 mg/kg on Day 1 and matching apixaban placebo tablets orally BID for 10 to 14 days.	
Reporting group title	Apixaban 2.5 mg and JNJ-64179375 Placebo IV
Reporting group description: Subjects received a single IV infusion of matching JNJ-64179375 placebo on Day 1 and apixaban 2.5 mg tablet orally BID for 10 to 14 days.	

### Primary: Number of Subjects with Treatment-emergent Bleeding Events (Clinical Events Committee [CEC]-adjudicated)

End point title	Number of Subjects with Treatment-emergent Bleeding Events (Clinical Events Committee [CEC]-adjudicated) <sup>[1]</sup>
End point description: Number of subjects with treatment-emergent bleeding events (adjudicated by CEC) were reported. Bleeding event (BE) was defined as the composite of major, clinically relevant nonmajor (CRNM), and minimal bleeding events assessed through the Day 10 to 14. Safety Analysis Set (SAS) included all randomized subjects who received at least 1 dose (partial or complete) of active study drug (JNJ-64179375 or apixaban).	
End point type	Primary
End point timeframe: Up to Day 10 to 14 (visit observation period)	

#### Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

End point values	JNJ-64179375 0.3 mg/kg and Apixaban Placebo	JNJ-64179375 0.6 mg/kg and Apixaban Placebo	JNJ-64179375 1.2 mg/kg and Apixaban Placebo	JNJ-64179375 1.8 mg/kg and Apixaban Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	40	42	122
Units: Subjects	2	0	5	1

<b>End point values</b>	Apixaban 2.5 mg and JNJ-64179375 Placebo IV			
Subject group type	Reporting group			
Number of subjects analysed	63			
Units: Subjects	4			

## Statistical analyses

No statistical analyses for this end point

## Primary: Number of Subjects With Total Venous Thromboembolism (VTE) (CEC-adjudicated)

End point title	Number of Subjects With Total Venous Thromboembolism (VTE) (CEC-adjudicated) <sup>[2]</sup>
-----------------	---

End point description:

Number of subjects with total VTE were reported. Total VTE was defined as the composite of CEC-adjudicated proximal and/or distal deep vein thrombosis (DVT) (asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic), nonfatal pulmonary embolism (PE), or any death assessed through the Day 10 to 14 visit. Modified Intent-to-treat (mITT) analysis set included all randomized subjects with an evaluable venography assessment or a confirmed symptomatic VTE event or any death. 1 subject had an asymptomatic distal clot in the non-operated leg which is not counted in the Total VTE and 2 subjects had symptomatic proximal clots at the Day 10 to 14 venography and are counted in both the asymptomatic proximal and symptomatic proximal groups.

End point type	Primary
----------------	---------

End point timeframe:

Up to Day 10 to 14 (visit observation period)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no inferential statistical analyses were performed.

<b>End point values</b>	JNJ-64179375 0.3 mg/kg and Apixaban Placebo	JNJ-64179375 0.6 mg/kg and Apixaban Placebo	JNJ-64179375 1.2 mg/kg and Apixaban Placebo	JNJ-64179375 1.8 mg/kg and Apixaban Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	33	30	97
Units: Subjects	10	9	9	31

<b>End point values</b>	Apixaban 2.5 mg and JNJ-64179375 Placebo IV			
Subject group type	Reporting group			
Number of subjects analysed	49			
Units: Subjects	6			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Composite of Major and CRNM Bleeding Events (CEC-adjudicated)

End point title	Number of Subjects With Composite of Major and CRNM Bleeding Events (CEC-adjudicated)
-----------------	---

End point description:

Number of subjects with composite of major and CRNM bleeding events were reported. Major Bleeding: Fatal bleeding; Bleeding that is symptomatic and occurs in critical area/organ and/or; Extrasurgical site bleeding causing fall in Hb level of 20 g/L or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; Surgical site bleeding that requires second intervention open, arthroscopic, endovascular, or hemarthrosis resulting in prolonged hospitalization or a deep wound infection and/or; Surgical site bleeding that is unexpected and prolonged and/or sufficiently large to cause hemodynamic instability. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria for BE to be defined as major BE and meets at least 1 of following: Epistaxis, Gastrointestinal bleed, Hematuria, Bruising/ecchymosis, Hemoptysis, Hematoma. Population included safety analysis set.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Day 10 to 14 (visit observation period)

<b>End point values</b>	JNJ-64179375 0.3 mg/kg and Apixaban Placebo	JNJ-64179375 0.6 mg/kg and Apixaban Placebo	JNJ-64179375 1.2 mg/kg and Apixaban Placebo	JNJ-64179375 1.8 mg/kg and Apixaban Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	40	42	122
Units: Subjects	0	0	0	0

<b>End point values</b>	Apixaban 2.5 mg and JNJ- 64179375 Placebo IV			
Subject group type	Reporting group			
Number of subjects analysed	63			
Units: Subjects	0			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Major Bleeding Events (CEC-adjudicated)

End point title	Number of Subjects With Major Bleeding Events (CEC-adjudicated)
-----------------	---

End point description:

Number of subjects with major bleeding events (CEC-adjudicated) were reported. Major bleeding: fatal bleeding or bleeding that is symptomatic and occurs in a critical area or organ in a non-operated joint,

or intramuscular with compartment syndrome, assessed in consultation with surgeon, and/or extra-surgical site bleeding causing a fall in hemoglobin (Hb) level of 20 grams per liter (g/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells, with temporal association within 24-48 hours to bleeding or surgical site bleeding that requires a second intervention open, arthroscopic, endovascular, or a hemarthrosis of sufficient size as to interfere with rehabilitation by delaying mobilization or delayed wound healing, resulting in prolonged hospitalization or a deep wound infection or Surgical site bleeding that is unexpected and prolonged or sufficiently large to cause hemodynamic instability, as assessed by surgeon. Population included safety analysis set.

End point type	Secondary
End point timeframe:	
Up to Day 10 to 14 (visit observation period)	

End point values	JNJ-64179375 0.3 mg/kg and Apixaban Placebo	JNJ-64179375 0.6 mg/kg and Apixaban Placebo	JNJ-64179375 1.2 mg/kg and Apixaban Placebo	JNJ-64179375 1.8 mg/kg and Apixaban Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	40	42	122
Units: Subjects	0	0	0	0

End point values	Apixaban 2.5 mg and JNJ- 64179375 Placebo IV			
Subject group type	Reporting group			
Number of subjects analysed	63			
Units: Subjects	0			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects With Clinically Relevant non-major (CRNM) Bleeding Events (CEC-adjudicated)

End point title	Number of Subjects With Clinically Relevant non-major (CRNM) Bleeding Events (CEC-adjudicated)
-----------------	--

End point description:

Number of subjects with CRNM bleeding events (adjudicated by CEC) were reported. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria for BE to be defined as major BE and meets at least 1 of following: Epistaxis, Gastrointestinal bleed, Hematuria, Bruising/ecchymosis, Hemoptysis, Hematoma. Safety analysis set included all randomized participants who received at least 1 dose (partial or complete) of active study drug.

End point type	Secondary
End point timeframe:	
Up to Day 10 to 14 (visit observation period)	

<b>End point values</b>	JNJ-64179375 0.3 mg/kg and Apixaban Placebo	JNJ-64179375 0.6 mg/kg and Apixaban Placebo	JNJ-64179375 1.2 mg/kg and Apixaban Placebo	JNJ-64179375 1.8 mg/kg and Apixaban Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	40	42	122
Units: Subjects	1	0	2	1

<b>End point values</b>	Apixaban 2.5 mg and JNJ- 64179375 Placebo IV			
Subject group type	Reporting group			
Number of subjects analysed	63			
Units: Subjects	0			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Major Bleeding or CRNM Bleeding Events (CEC-adjudicated)

End point title	Number of Subjects With Major Bleeding or CRNM Bleeding Events (CEC-adjudicated)
-----------------	--

End point description:

Number of subjects with major bleeding or CRNM bleeding events (adjudicated by CEC) were reported. Major Bleeding: Fatal bleeding; Bleeding that is symptomatic and occurs in critical area/organ and/or; Extrasurgical site bleeding causing fall in Hb level of 20 g/L or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; Surgical site bleeding that requires second intervention open, arthroscopic, endovascular, or hemarthrosis resulting in prolonged hospitalization or a deep wound infection and/or; Surgical site bleeding that is unexpected and prolonged and/or sufficiently large to cause hemodynamic instability. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria for bleeding events to be defined as major bleeding event and meets at least 1 of following: Epistaxis, Gastrointestinal bleed, Hematuria, Bruising/ecchymosis, Hemoptysis, Hematoma. SAS was analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Day 10 and 14 (visit observation period)

<b>End point values</b>	JNJ-64179375 0.3 mg/kg and Apixaban Placebo	JNJ-64179375 0.6 mg/kg and Apixaban Placebo	JNJ-64179375 1.2 mg/kg and Apixaban Placebo	JNJ-64179375 1.8 mg/kg and Apixaban Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	40	42	122
Units: Subjects	1	0	2	1

<b>End point values</b>	Apixaban 2.5 mg and JNJ-64179375 Placebo IV			
Subject group type	Reporting group			
Number of subjects analysed	63			
Units: Subjects	0			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects With Minimal Bleeding Events (CEC-adjudicated)

End point title	Number of Subjects With Minimal Bleeding Events (CEC-adjudicated)
End point description: Number of subjects with minimal bleeding events (adjudicated by CEC) were reported. Minimal bleeding event was defined as any bleeding event not met major or CRNM criteria. Safety analysis set included all randomized subjects who received at least 1 dose (partial or complete) of active study drug.	
End point type	Secondary
End point timeframe: Up to Day 10 to 14 (visit observation period)	

<b>End point values</b>	JNJ-64179375 0.3 mg/kg and Apixaban Placebo	JNJ-64179375 0.6 mg/kg and Apixaban Placebo	JNJ-64179375 1.2 mg/kg and Apixaban Placebo	JNJ-64179375 1.8 mg/kg and Apixaban Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	40	42	122
Units: Subjects	2	0	4	0

<b>End point values</b>	Apixaban 2.5 mg and JNJ-64179375 Placebo IV			
Subject group type	Reporting group			
Number of subjects analysed	63			
Units: Subjects	4			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects With Major VTE (CEC-adjudicated)

End point title	Number of Subjects With Major VTE (CEC-adjudicated)
-----------------	---

**End point description:**

Number of subjects with major VTE (adjudicated by CEC) were reported. Major VTE was defined as a composite of proximal DVT (asymptomatic confirmed by venography or objectively confirmed symptomatic), nonfatal PE, or any death. mITT analysis set included all randomized subjects with an evaluable venography assessment or a confirmed symptomatic VTE event or any death. 2 subjects had symptomatic proximal clots at the Day 10 to 14 venography and are counted in both the asymptomatic proximal and symptomatic proximal groups.

End point type	Secondary
----------------	-----------

**End point timeframe:**

Up to Day 10 to 14 (visit observation period)

<b>End point values</b>	JNJ-64179375 0.3 mg/kg and Apixaban Placebo	JNJ-64179375 0.6 mg/kg and Apixaban Placebo	JNJ-64179375 1.2 mg/kg and Apixaban Placebo	JNJ-64179375 1.8 mg/kg and Apixaban Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	33	30	97
Units: Subjects	2	2	1	7

<b>End point values</b>	Apixaban 2.5 mg and JNJ- 64179375 Placebo IV			
Subject group type	Reporting group			
Number of subjects analysed	49			
Units: Subjects	0			

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Number of Subjects With Proximal Deep Vein Thrombosis (DVT) (CEC-adjudicated)**

End point title	Number of Subjects With Proximal Deep Vein Thrombosis (DVT) (CEC-adjudicated)
-----------------	---

**End point description:**

Number of subjects with proximal DVT (adjudicated by CEC) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic. mITT analysis set included all randomized subjects with an evaluable venography assessment or a confirmed symptomatic VTE event or any death. 2 subjects had symptomatic proximal clots at the Day 10 to 14 venography and are counted in both the asymptomatic proximal and symptomatic proximal groups.

End point type	Secondary
----------------	-----------

**End point timeframe:**

Up to Day 10 to 14 (visit observation period)

End point values	JNJ-64179375 0.3 mg/kg and Apixaban Placebo	JNJ-64179375 0.6 mg/kg and Apixaban Placebo	JNJ-64179375 1.2 mg/kg and Apixaban Placebo	JNJ-64179375 1.8 mg/kg and Apixaban Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	33	30	97
Units: Subjects				
Asymptomatic	1	2	0	3
Symptomatic	0	0	0	2

End point values	Apixaban 2.5 mg and JNJ- 64179375 Placebo IV			
Subject group type	Reporting group			
Number of subjects analysed	49			
Units: Subjects				
Asymptomatic	0			
Symptomatic	0			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Nonfatal Pulmonary Embolism (PE) (CEC- adjudicated)

End point title	Number of Subjects With Nonfatal Pulmonary Embolism (PE) (CEC- adjudicated)
-----------------	---

End point description:

Number of subjects with nonfatal PE (adjudicated by CEC) were reported. mITT analysis set included all randomized subjects with an evaluable venography assessment or a confirmed symptomatic VTE event, or any death.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Day 10 to 14 (visit observation period)

End point values	JNJ-64179375 0.3 mg/kg and Apixaban Placebo	JNJ-64179375 0.6 mg/kg and Apixaban Placebo	JNJ-64179375 1.2 mg/kg and Apixaban Placebo	JNJ-64179375 1.8 mg/kg and Apixaban Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	33	30	97
Units: Subjects	0	0	0	0



<b>End point values</b>	Apixaban 2.5 mg and JNJ-64179375 Placebo IV			
Subject group type	Reporting group			
Number of subjects analysed	49			
Units: Subjects	0			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Death (CEC-adjudicated)

End point title	Number of Subjects With Death (CEC-adjudicated)
End point description: Number of subjects with death (adjudicated by CEC) were reported. mITT analysis set included all randomized subjects with an evaluable venography assessment or a confirmed symptomatic VTE event, or any death.	
End point type	Secondary
End point timeframe: Up to 10 to 14 (visit observation period)	

<b>End point values</b>	JNJ-64179375 0.3 mg/kg and Apixaban Placebo	JNJ-64179375 0.6 mg/kg and Apixaban Placebo	JNJ-64179375 1.2 mg/kg and Apixaban Placebo	JNJ-64179375 1.8 mg/kg and Apixaban Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	33	30	97
Units: Subjects	0	0	0	0

<b>End point values</b>	Apixaban 2.5 mg and JNJ-64179375 Placebo IV			
Subject group type	Reporting group			
Number of subjects analysed	49			
Units: Subjects	0			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Proximal and Distal DVT (CEC-adjudicated)

End point title	Number of Subjects With Proximal and Distal DVT (CEC-adjudicated)
-----------------	---

**End point description:**

Number of subjects with proximal and distal DVT (adjudicated by CEC) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic. mITT analysis set included all randomized subjects with an evaluable venography assessment or a confirmed symptomatic VTE event, or any death. 2 subjects had symptomatic proximal clots at the Day 10 to 14 venography and are counted in both the asymptomatic proximal and symptomatic proximal groups.

End point type	Secondary
----------------	-----------

**End point timeframe:**

Up to Day 10 to 14 (visit observation period)

<b>End point values</b>	JNJ-64179375 0.3 mg/kg and Apixaban Placebo	JNJ-64179375 0.6 mg/kg and Apixaban Placebo	JNJ-64179375 1.2 mg/kg and Apixaban Placebo	JNJ-64179375 1.8 mg/kg and Apixaban Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	33	30	97
Units: Subjects				
Asymptomatic	1	0	1	4
Symptomatic	0	0	0	0

<b>End point values</b>	Apixaban 2.5 mg and JNJ- 64179375 Placebo IV			
Subject group type	Reporting group			
Number of subjects analysed	49			
Units: Subjects				
Asymptomatic	0			
Symptomatic	0			

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Number of Subjects With Distal DVT (CEC-adjudicated)**

End point title	Number of Subjects With Distal DVT (CEC-adjudicated)
-----------------	--

**End point description:**

Number of subjects with distal DVT (adjudicated by CEC) were reported. mITT analysis set included all randomized participants with an evaluable venography assessment or a confirmed symptomatic VTE event, or any death.

End point type	Secondary
----------------	-----------

**End point timeframe:**

Up to Day 10 to 14 (visit observation period)

<b>End point values</b>	JNJ-64179375 0.3 mg/kg and Apixaban Placebo	JNJ-64179375 0.6 mg/kg and Apixaban Placebo	JNJ-64179375 1.2 mg/kg and Apixaban Placebo	JNJ-64179375 1.8 mg/kg and Apixaban Placebo
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	30	33	30	97
Units: Subjects				
Asymptomatic	8	7	8	24
Symptomatic	0	0	0	1

<b>End point values</b>	Apixaban 2.5 mg and JNJ- 64179375 Placebo IV			
Subject group type	Reporting group			
Number of subjects analysed	49			
Units: Subjects				
Asymptomatic	6			
Symptomatic	1			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to 18 weeks

Adverse event reporting additional description:

Safety Analysis set included all randomized subjects who received at least 1 dose (partial or complete) of active study drug (JNJ-64179375 or apixaban).

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	21.0
--------------------	------

### Reporting groups

Reporting group title	JNJ-64179375 0.3 mg/kg and Apixaban Placebo
-----------------------	---

Reporting group description:

Subjects received a single intravenous (IV) infusion of JNJ-64179375 0.3 milligrams per kilogram (mg/kg) on Day 1 and matching apixaban placebo tablets orally twice daily (BID) for 10 to 14 days.

Reporting group title	JNJ-64179375 0.6 mg/kg and Apixaban Placebo
-----------------------	---

Reporting group description:

Subjects received a single IV infusion of JNJ-64179375 0.6 mg/kg on Day 1 and matching apixaban placebo tablets orally BID for 10 to 14 days.

Reporting group title	JNJ-64179375 1.2 mg/kg and Apixaban Placebo
-----------------------	---

Reporting group description:

Subjects received a single IV infusion of JNJ-64179375 1.2 mg/kg on Day 1 and matching apixaban placebo tablets orally BID for 10 to 14 days.

Reporting group title	JNJ-64179375 1.8 mg/kg and Apixaban Placebo
-----------------------	---

Reporting group description:

Subjects received a single IV infusion of JNJ-64179375 1.8 mg/kg on Day 1 and matching apixaban placebo tablets orally BID for 10 to 14 days.

Reporting group title	Apixaban 2.5 mg and JNJ-64179375 Placebo IV
-----------------------	---

Reporting group description:

Subjects received a single IV infusion of matching JNJ-64179375 placebo on Day 1 and apixaban 2.5 mg tablet orally BID for 10 to 14 days.

Serious adverse events	JNJ-64179375 0.3 mg/kg and Apixaban Placebo	JNJ-64179375 0.6 mg/kg and Apixaban Placebo	JNJ-64179375 1.2 mg/kg and Apixaban Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 38 (5.26%)	2 / 40 (5.00%)	4 / 42 (9.52%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal Cell Carcinoma			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Bladder Cancer Stage 0, with Cancer in Situ			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Overdose			
subjects affected / exposed	1 / 38 (2.63%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative Wound Complication			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon Rupture			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound Haemorrhage			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Bloody Discharge			
subjects affected / exposed	1 / 38 (2.63%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep Vein Thrombosis			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post Thrombotic Syndrome			

subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Angina Unstable			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Transient Ischaemic Attack			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Impaired Healing			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema Peripheral			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral Swelling			
subjects affected / exposed	0 / 38 (0.00%)	1 / 40 (2.50%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Ascites			

subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Primary Hyperaldosteronism			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 38 (0.00%)	1 / 40 (2.50%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemarthrosis			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint Contracture			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Herpes Zoster			

subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative Wound Infection			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary Tract Infection			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	JNJ-64179375 1.8 mg/kg and Apixaban Placebo	Apixaban 2.5 mg and JNJ-64179375 Placebo IV	
Total subjects affected by serious adverse events			
subjects affected / exposed	13 / 122 (10.66%)	5 / 63 (7.94%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal Cell Carcinoma			
subjects affected / exposed	1 / 122 (0.82%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder Cancer Stage 0, with Cancer in Situ			
subjects affected / exposed	1 / 122 (0.82%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Overdose			



subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative Wound Complication			
subjects affected / exposed	1 / 122 (0.82%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tendon Rupture			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound Haemorrhage			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Bloody Discharge			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep Vein Thrombosis			
subjects affected / exposed	6 / 122 (4.92%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 6	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post Thrombotic Syndrome			
subjects affected / exposed	1 / 122 (0.82%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Angina Unstable			
subjects affected / exposed	1 / 122 (0.82%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			

Transient Ischaemic Attack			
subjects affected / exposed	0 / 122 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Impaired Healing			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oedema Peripheral			
subjects affected / exposed	0 / 122 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral Swelling			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	0 / 122 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Ascites			
subjects affected / exposed	0 / 122 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	1 / 122 (0.82%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Primary Hyperaldosteronism			

subjects affected / exposed	1 / 122 (0.82%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Musculoskeletal and connective tissue disorders</b>			
Arthralgia			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arthritis			
subjects affected / exposed	1 / 122 (0.82%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemarthrosis			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Joint Contracture			
subjects affected / exposed	1 / 122 (0.82%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Infections and infestations</b>			
Herpes Zoster			
subjects affected / exposed	1 / 122 (0.82%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative Wound Infection			
subjects affected / exposed	0 / 122 (0.00%)	1 / 63 (1.59%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Urinary Tract Infection			
subjects affected / exposed	1 / 122 (0.82%)	0 / 63 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 2 %

<b>Non-serious adverse events</b>	JNJ-64179375 0.3 mg/kg and Apixaban Placebo	JNJ-64179375 0.6 mg/kg and Apixaban Placebo	JNJ-64179375 1.2 mg/kg and Apixaban Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	19 / 38 (50.00%)	17 / 40 (42.50%)	26 / 42 (61.90%)
Vascular disorders			
Bloody Discharge			
subjects affected / exposed	1 / 38 (2.63%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences (all)	1	0	0
Deep Vein Thrombosis			
subjects affected / exposed	2 / 38 (5.26%)	1 / 40 (2.50%)	0 / 42 (0.00%)
occurrences (all)	2	1	0
Haematoma			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	1
Haemorrhage			
subjects affected / exposed	0 / 38 (0.00%)	1 / 40 (2.50%)	0 / 42 (0.00%)
occurrences (all)	0	1	0
Hypertension			
subjects affected / exposed	1 / 38 (2.63%)	1 / 40 (2.50%)	0 / 42 (0.00%)
occurrences (all)	1	1	0
Hypotension			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	2
Peripheral Venous Disease			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences (all)	0	0	0
Thrombophlebitis			
subjects affected / exposed	2 / 38 (5.26%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	2	0	1

General disorders and administration site conditions			
Catheter Site Haemorrhage			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	1
Fat Necrosis			
subjects affected / exposed	0 / 38 (0.00%)	1 / 40 (2.50%)	0 / 42 (0.00%)
occurrences (all)	0	1	0
Feeling Hot			
subjects affected / exposed	1 / 38 (2.63%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences (all)	1	0	0
Hyperthermia			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	2 / 42 (4.76%)
occurrences (all)	0	0	2
Impaired Healing			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	2
Injection Site Irritation			
subjects affected / exposed	1 / 38 (2.63%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences (all)	1	0	0
Non-Cardiac Chest Pain			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	1
Oedema Peripheral			
subjects affected / exposed	1 / 38 (2.63%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences (all)	1	0	0
Peripheral Swelling			
subjects affected / exposed	0 / 38 (0.00%)	1 / 40 (2.50%)	0 / 42 (0.00%)
occurrences (all)	0	1	0
Pyrexia			
subjects affected / exposed	6 / 38 (15.79%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences (all)	9	0	0
Respiratory, thoracic and mediastinal disorders			
Epistaxis			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	1
Pulmonary Embolism			

subjects affected / exposed occurrences (all)	0 / 38 (0.00%) 0	0 / 40 (0.00%) 0	1 / 42 (2.38%) 1
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 38 (2.63%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences (all)	1	0	0
Insomnia			
subjects affected / exposed	0 / 38 (0.00%)	1 / 40 (2.50%)	1 / 42 (2.38%)
occurrences (all)	0	1	1
Restlessness			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	1
Investigations			
Blood Glucose Increased			
subjects affected / exposed	1 / 38 (2.63%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	1	0	1
Blood Thyroid Stimulating Hormone Increased			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	1
Blood Triglycerides Increased			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	1
Body Temperature Increased			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	1
Cardiovascular Evaluation			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	1
Gamma-Glutamyltransferase Decreased			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	1
Platelet Count Increased			
subjects affected / exposed	0 / 38 (0.00%)	1 / 40 (2.50%)	0 / 42 (0.00%)
occurrences (all)	0	1	0
Injury, poisoning and procedural complications			

Contusion			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	3 / 42 (7.14%)
occurrences (all)	0	0	5
Patella Fracture			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	1
Post Procedural Haematoma			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	1
Post Procedural Swelling			
subjects affected / exposed	0 / 38 (0.00%)	1 / 40 (2.50%)	0 / 42 (0.00%)
occurrences (all)	0	1	0
Procedural Haemorrhage			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	1
Procedural Pain			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	1
Tendon Rupture			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	1
Wound Haemorrhage			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	3 / 42 (7.14%)
occurrences (all)	0	0	4
Cardiac disorders			
Palpitations			
subjects affected / exposed	1 / 38 (2.63%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences (all)	1	0	0
Nervous system disorders			
Dizziness Exertional			
subjects affected / exposed	1 / 38 (2.63%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences (all)	1	0	0
Dizziness Postural			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	1
Headache			

subjects affected / exposed occurrences (all)	0 / 38 (0.00%) 0	0 / 40 (0.00%) 0	1 / 42 (2.38%) 1
Neuralgia subjects affected / exposed occurrences (all)	0 / 38 (0.00%) 0	1 / 40 (2.50%) 1	0 / 42 (0.00%) 0
Syncope subjects affected / exposed occurrences (all)	0 / 38 (0.00%) 0	1 / 40 (2.50%) 1	0 / 42 (0.00%) 0
Blood and lymphatic system disorders Lymphadenopathy subjects affected / exposed occurrences (all)	0 / 38 (0.00%) 0	1 / 40 (2.50%) 1	0 / 42 (0.00%) 0
Thrombocytosis subjects affected / exposed occurrences (all)	0 / 38 (0.00%) 0	1 / 40 (2.50%) 1	0 / 42 (0.00%) 0
Ear and labyrinth disorders Vertigo subjects affected / exposed occurrences (all)	0 / 38 (0.00%) 0	0 / 40 (0.00%) 0	1 / 42 (2.38%) 1
Eye disorders Conjunctival Haemorrhage subjects affected / exposed occurrences (all)	1 / 38 (2.63%) 1	0 / 40 (0.00%) 0	0 / 42 (0.00%) 0
Gastrointestinal disorders Aphthous Ulcer subjects affected / exposed occurrences (all)	0 / 38 (0.00%) 0	0 / 40 (0.00%) 0	1 / 42 (2.38%) 1
Constipation subjects affected / exposed occurrences (all)	2 / 38 (5.26%) 2	0 / 40 (0.00%) 0	0 / 42 (0.00%) 0
Diarrhoea subjects affected / exposed occurrences (all)	1 / 38 (2.63%) 2	2 / 40 (5.00%) 2	0 / 42 (0.00%) 0
Food Poisoning subjects affected / exposed occurrences (all)	0 / 38 (0.00%) 0	0 / 40 (0.00%) 0	1 / 42 (2.38%) 1
Nausea			



subjects affected / exposed	1 / 38 (2.63%)	3 / 40 (7.50%)	5 / 42 (11.90%)
occurrences (all)	1	3	5
Stomatitis			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	1
Vomiting			
subjects affected / exposed	0 / 38 (0.00%)	1 / 40 (2.50%)	2 / 42 (4.76%)
occurrences (all)	0	1	2
Skin and subcutaneous tissue disorders			
Decubitus Ulcer			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	1
Dermatitis Contact			
subjects affected / exposed	0 / 38 (0.00%)	1 / 40 (2.50%)	0 / 42 (0.00%)
occurrences (all)	0	1	0
Dry Skin			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	1
Ecchymosis			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	1
Pruritus			
subjects affected / exposed	0 / 38 (0.00%)	1 / 40 (2.50%)	0 / 42 (0.00%)
occurrences (all)	0	1	0
Pruritus Generalised			
subjects affected / exposed	1 / 38 (2.63%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences (all)	1	0	0
Rash			
subjects affected / exposed	0 / 38 (0.00%)	2 / 40 (5.00%)	1 / 42 (2.38%)
occurrences (all)	0	2	1
Rash Pruritic			
subjects affected / exposed	0 / 38 (0.00%)	1 / 40 (2.50%)	0 / 42 (0.00%)
occurrences (all)	0	1	0
Renal and urinary disorders			
Renal Colic			

subjects affected / exposed occurrences (all)	0 / 38 (0.00%) 0	1 / 40 (2.50%) 1	0 / 42 (0.00%) 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 38 (2.63%)	0 / 40 (0.00%)	5 / 42 (11.90%)
occurrences (all)	1	0	5
Arthritis			
subjects affected / exposed	0 / 38 (0.00%)	1 / 40 (2.50%)	0 / 42 (0.00%)
occurrences (all)	0	1	0
Haemarthrosis			
subjects affected / exposed	1 / 38 (2.63%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences (all)	1	0	0
Osteoarthritis			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	1
Pain in Extremity			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	1
Infections and infestations			
Cystitis			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	1
Gastroenteritis			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	1 / 42 (2.38%)
occurrences (all)	0	0	2
Urinary Tract Infection			
subjects affected / exposed	0 / 38 (0.00%)	0 / 40 (0.00%)	3 / 42 (7.14%)
occurrences (all)	0	0	6
Wound Infection			
subjects affected / exposed	2 / 38 (5.26%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences (all)	2	0	0
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	1 / 38 (2.63%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences (all)	1	0	0
Hyperkalaemia			

subjects affected / exposed	1 / 38 (2.63%)	0 / 40 (0.00%)	0 / 42 (0.00%)
occurrences (all)	1	0	0
Hyperuricaemia			
subjects affected / exposed	0 / 38 (0.00%)	1 / 40 (2.50%)	0 / 42 (0.00%)
occurrences (all)	0	1	0

<b>Non-serious adverse events</b>	JNJ-64179375 1.8 mg/kg and Apixaban Placebo	Apixaban 2.5 mg and JNJ-64179375 Placebo IV	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	37 / 122 (30.33%)	20 / 63 (31.75%)	
Vascular disorders			
Bloody Discharge			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Deep Vein Thrombosis			
subjects affected / exposed	2 / 122 (1.64%)	3 / 63 (4.76%)	
occurrences (all)	2	3	
Haematoma			
subjects affected / exposed	1 / 122 (0.82%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Haemorrhage			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Hypertension			
subjects affected / exposed	4 / 122 (3.28%)	2 / 63 (3.17%)	
occurrences (all)	4	2	
Hypotension			
subjects affected / exposed	0 / 122 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Peripheral Venous Disease			
subjects affected / exposed	3 / 122 (2.46%)	0 / 63 (0.00%)	
occurrences (all)	3	0	
Thrombophlebitis			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
General disorders and administration site conditions			

Catheter Site Haemorrhage subjects affected / exposed occurrences (all)	0 / 122 (0.00%) 0	0 / 63 (0.00%) 0	
Fat Necrosis subjects affected / exposed occurrences (all)	0 / 122 (0.00%) 0	0 / 63 (0.00%) 0	
Feeling Hot subjects affected / exposed occurrences (all)	0 / 122 (0.00%) 0	0 / 63 (0.00%) 0	
Hyperthermia subjects affected / exposed occurrences (all)	0 / 122 (0.00%) 0	0 / 63 (0.00%) 0	
Impaired Healing subjects affected / exposed occurrences (all)	0 / 122 (0.00%) 0	0 / 63 (0.00%) 0	
Injection Site Irritation subjects affected / exposed occurrences (all)	0 / 122 (0.00%) 0	0 / 63 (0.00%) 0	
Non-Cardiac Chest Pain subjects affected / exposed occurrences (all)	0 / 122 (0.00%) 0	0 / 63 (0.00%) 0	
Oedema Peripheral subjects affected / exposed occurrences (all)	2 / 122 (1.64%) 2	0 / 63 (0.00%) 0	
Peripheral Swelling subjects affected / exposed occurrences (all)	0 / 122 (0.00%) 0	0 / 63 (0.00%) 0	
Pyrexia subjects affected / exposed occurrences (all)	8 / 122 (6.56%) 10	1 / 63 (1.59%) 1	
Respiratory, thoracic and mediastinal disorders			
Epistaxis subjects affected / exposed occurrences (all)	1 / 122 (0.82%) 1	1 / 63 (1.59%) 1	
Pulmonary Embolism			

subjects affected / exposed occurrences (all)	1 / 122 (0.82%) 1	0 / 63 (0.00%) 0	
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Insomnia			
subjects affected / exposed	0 / 122 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Restlessness			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Investigations			
Blood Glucose Increased			
subjects affected / exposed	1 / 122 (0.82%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Blood Thyroid Stimulating Hormone Increased			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Blood Triglycerides Increased			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Body Temperature Increased			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Cardiovascular Evaluation			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Gamma-Glutamyltransferase Decreased			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Platelet Count Increased			
subjects affected / exposed	1 / 122 (0.82%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Injury, poisoning and procedural complications			

Contusion			
subjects affected / exposed	0 / 122 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Patella Fracture			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Post Procedural Haematoma			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Post Procedural Swelling			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Procedural Haemorrhage			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Procedural Pain			
subjects affected / exposed	4 / 122 (3.28%)	2 / 63 (3.17%)	
occurrences (all)	4	2	
Tendon Rupture			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Wound Haemorrhage			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Cardiac disorders			
Palpitations			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Nervous system disorders			
Dizziness Exertional			
subjects affected / exposed	0 / 122 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Dizziness Postural			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Headache			

subjects affected / exposed occurrences (all)	3 / 122 (2.46%) 3	1 / 63 (1.59%) 2	
Neuralgia subjects affected / exposed occurrences (all)	0 / 122 (0.00%) 0	0 / 63 (0.00%) 0	
Syncope subjects affected / exposed occurrences (all)	0 / 122 (0.00%) 0	0 / 63 (0.00%) 0	
Blood and lymphatic system disorders Lymphadenopathy subjects affected / exposed occurrences (all)	0 / 122 (0.00%) 0	0 / 63 (0.00%) 0	
Thrombocytosis subjects affected / exposed occurrences (all)	0 / 122 (0.00%) 0	1 / 63 (1.59%) 1	
Ear and labyrinth disorders Vertigo subjects affected / exposed occurrences (all)	1 / 122 (0.82%) 1	1 / 63 (1.59%) 1	
Eye disorders Conjunctival Haemorrhage subjects affected / exposed occurrences (all)	0 / 122 (0.00%) 0	0 / 63 (0.00%) 0	
Gastrointestinal disorders Aphthous Ulcer subjects affected / exposed occurrences (all)	0 / 122 (0.00%) 0	0 / 63 (0.00%) 0	
Constipation subjects affected / exposed occurrences (all)	1 / 122 (0.82%) 1	2 / 63 (3.17%) 3	
Diarrhoea subjects affected / exposed occurrences (all)	2 / 122 (1.64%) 2	1 / 63 (1.59%) 1	
Food Poisoning subjects affected / exposed occurrences (all)	0 / 122 (0.00%) 0	0 / 63 (0.00%) 0	
Nausea			

subjects affected / exposed occurrences (all)	3 / 122 (2.46%) 3	0 / 63 (0.00%) 0	
Stomatitis			
subjects affected / exposed occurrences (all)	0 / 122 (0.00%) 0	0 / 63 (0.00%) 0	
Vomiting			
subjects affected / exposed occurrences (all)	3 / 122 (2.46%) 3	0 / 63 (0.00%) 0	
Skin and subcutaneous tissue disorders			
Decubitus Ulcer			
subjects affected / exposed occurrences (all)	1 / 122 (0.82%) 1	0 / 63 (0.00%) 0	
Dermatitis Contact			
subjects affected / exposed occurrences (all)	0 / 122 (0.00%) 0	0 / 63 (0.00%) 0	
Dry Skin			
subjects affected / exposed occurrences (all)	0 / 122 (0.00%) 0	0 / 63 (0.00%) 0	
Ecchymosis			
subjects affected / exposed occurrences (all)	0 / 122 (0.00%) 0	0 / 63 (0.00%) 0	
Pruritus			
subjects affected / exposed occurrences (all)	1 / 122 (0.82%) 1	0 / 63 (0.00%) 0	
Pruritus Generalised			
subjects affected / exposed occurrences (all)	0 / 122 (0.00%) 0	0 / 63 (0.00%) 0	
Rash			
subjects affected / exposed occurrences (all)	0 / 122 (0.00%) 0	0 / 63 (0.00%) 0	
Rash Pruritic			
subjects affected / exposed occurrences (all)	0 / 122 (0.00%) 0	0 / 63 (0.00%) 0	
Renal and urinary disorders			
Renal Colic			



subjects affected / exposed occurrences (all)	0 / 122 (0.00%) 0	0 / 63 (0.00%) 0	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	3 / 122 (2.46%)	0 / 63 (0.00%)	
occurrences (all)	3	0	
Arthritis			
subjects affected / exposed	2 / 122 (1.64%)	0 / 63 (0.00%)	
occurrences (all)	2	0	
Haemarthrosis			
subjects affected / exposed	1 / 122 (0.82%)	1 / 63 (1.59%)	
occurrences (all)	1	1	
Osteoarthritis			
subjects affected / exposed	0 / 122 (0.00%)	1 / 63 (1.59%)	
occurrences (all)	0	1	
Pain in Extremity			
subjects affected / exposed	2 / 122 (1.64%)	1 / 63 (1.59%)	
occurrences (all)	2	1	
Infections and infestations			
Cystitis			
subjects affected / exposed	1 / 122 (0.82%)	0 / 63 (0.00%)	
occurrences (all)	1	0	
Gastroenteritis			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Urinary Tract Infection			
subjects affected / exposed	1 / 122 (0.82%)	1 / 63 (1.59%)	
occurrences (all)	1	1	
Wound Infection			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Hyperkalaemia			

subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	
Hyperuricaemia			
subjects affected / exposed	0 / 122 (0.00%)	0 / 63 (0.00%)	
occurrences (all)	0	0	

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported